Heart failure & cardiomyopathiesCohort study
Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study
- Retrospective cohort study
- propensity-score matched
- population-based
Authors' conclusion
The use of SGLT2i was associated with a decreased risk of adverse clinical outcomes among patients with HCM with concurrent diabetes on antidiabetic drugs.
Study context
- Population
- Patients with hypertrophic cardiomyopathy (HCM) and diabetes on antidiabetic drugs, Korean National Health Insurance Service database, 2018–2022matched cohort
- Exposure
- SGLT2 inhibitor use vs no use
- Outcome
- Composite of:
- All-cause death
- Heart failure (HF) hospitalization
- Follow-up
- Median 3.1 years
Main finding
As reported in the abstract
Hazard ratio
0.76
95% CI 0.67–0.86
SGLT2i vs No SGLT2i
HR 0.76 (95% CI 0.67–0.86)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause death | 0.56 (0.46–0.68) | |
| HF hospitalization | 0.82 (0.72–0.94) | |
| Sudden cardiac death | 0.50 (0.33–0.77) | |
| Ischaemic stroke | 0.74 (0.62–0.88) | |
| 0.20.5125Hazard ratio (log scale) |
Primary outcome by age, sex and AF (subgroups)
- No significant interactions
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study. Eur J Prev Cardiol. Published 22 November 2024. doi:10.1093/eurjpc/zwae345
Summarised from the published abstract; every number is checked against it